TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

Álvaro de Mingo Pulido, Alycia Gardner, Shandi Hiebler, Hatem Soliman, Hope S. Rugo, Matthew F. Krummel, Lisa Coussens, Brian Ruffell

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Intratumoral CD103+ dendritic cells (DCs) are necessary for anti-tumor immunity. Here we evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast cancer and identified expression of TIM-3 as a target for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in models of triple-negative and luminal B disease, with no evidence of toxicity. Combined efficacy was CD8+ T cell dependent and associated with increased granzyme B expression; however, TIM-3 expression was predominantly localized to myeloid cells in both human and murine tumors. Gene expression analysis identified upregulation of Cxcl9 within intratumoral DCs during combination therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency. de Mingo Pulido et al. show that intratumoral CD103+ dendritic cells (DCs) highly express TIM-3. Anti-TIM-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells, thereby improving paclitaxel's therapeutic activity in breast cancer models.

Original languageEnglish (US)
Pages (from-to)60-74.e6
JournalCancer Cell
Volume33
Issue number1
DOIs
StatePublished - Jan 8 2018

Fingerprint

Dendritic Cells
Breast Neoplasms
Drug Therapy
Paclitaxel
T-Lymphocytes
Granzymes
Myeloid Cells
Therapeutics
Antibody Formation
Immunity
Neoplasms
Up-Regulation
Gene Expression
Antibodies

Keywords

  • breast cancer
  • chemotherapy
  • dendritic cells
  • galectin-9
  • immunotherapy
  • paclitaxel
  • TIM-3

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., ... Ruffell, B. (2018). TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 33(1), 60-74.e6. https://doi.org/10.1016/j.ccell.2017.11.019

TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. / de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi; Soliman, Hatem; Rugo, Hope S.; Krummel, Matthew F.; Coussens, Lisa; Ruffell, Brian.

In: Cancer Cell, Vol. 33, No. 1, 08.01.2018, p. 60-74.e6.

Research output: Contribution to journalArticle

de Mingo Pulido, Á, Gardner, A, Hiebler, S, Soliman, H, Rugo, HS, Krummel, MF, Coussens, L & Ruffell, B 2018, 'TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer', Cancer Cell, vol. 33, no. 1, pp. 60-74.e6. https://doi.org/10.1016/j.ccell.2017.11.019
de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF et al. TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018 Jan 8;33(1):60-74.e6. https://doi.org/10.1016/j.ccell.2017.11.019
de Mingo Pulido, Álvaro ; Gardner, Alycia ; Hiebler, Shandi ; Soliman, Hatem ; Rugo, Hope S. ; Krummel, Matthew F. ; Coussens, Lisa ; Ruffell, Brian. / TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. In: Cancer Cell. 2018 ; Vol. 33, No. 1. pp. 60-74.e6.
@article{373a26f2dd9d48778fbf6000db5ea4cb,
title = "TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer",
abstract = "Intratumoral CD103+ dendritic cells (DCs) are necessary for anti-tumor immunity. Here we evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast cancer and identified expression of TIM-3 as a target for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in models of triple-negative and luminal B disease, with no evidence of toxicity. Combined efficacy was CD8+ T cell dependent and associated with increased granzyme B expression; however, TIM-3 expression was predominantly localized to myeloid cells in both human and murine tumors. Gene expression analysis identified upregulation of Cxcl9 within intratumoral DCs during combination therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency. de Mingo Pulido et al. show that intratumoral CD103+ dendritic cells (DCs) highly express TIM-3. Anti-TIM-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells, thereby improving paclitaxel's therapeutic activity in breast cancer models.",
keywords = "breast cancer, chemotherapy, dendritic cells, galectin-9, immunotherapy, paclitaxel, TIM-3",
author = "{de Mingo Pulido}, {\'A}lvaro and Alycia Gardner and Shandi Hiebler and Hatem Soliman and Rugo, {Hope S.} and Krummel, {Matthew F.} and Lisa Coussens and Brian Ruffell",
year = "2018",
month = "1",
day = "8",
doi = "10.1016/j.ccell.2017.11.019",
language = "English (US)",
volume = "33",
pages = "60--74.e6",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

AU - de Mingo Pulido, Álvaro

AU - Gardner, Alycia

AU - Hiebler, Shandi

AU - Soliman, Hatem

AU - Rugo, Hope S.

AU - Krummel, Matthew F.

AU - Coussens, Lisa

AU - Ruffell, Brian

PY - 2018/1/8

Y1 - 2018/1/8

N2 - Intratumoral CD103+ dendritic cells (DCs) are necessary for anti-tumor immunity. Here we evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast cancer and identified expression of TIM-3 as a target for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in models of triple-negative and luminal B disease, with no evidence of toxicity. Combined efficacy was CD8+ T cell dependent and associated with increased granzyme B expression; however, TIM-3 expression was predominantly localized to myeloid cells in both human and murine tumors. Gene expression analysis identified upregulation of Cxcl9 within intratumoral DCs during combination therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency. de Mingo Pulido et al. show that intratumoral CD103+ dendritic cells (DCs) highly express TIM-3. Anti-TIM-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells, thereby improving paclitaxel's therapeutic activity in breast cancer models.

AB - Intratumoral CD103+ dendritic cells (DCs) are necessary for anti-tumor immunity. Here we evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast cancer and identified expression of TIM-3 as a target for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in models of triple-negative and luminal B disease, with no evidence of toxicity. Combined efficacy was CD8+ T cell dependent and associated with increased granzyme B expression; however, TIM-3 expression was predominantly localized to myeloid cells in both human and murine tumors. Gene expression analysis identified upregulation of Cxcl9 within intratumoral DCs during combination therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency. de Mingo Pulido et al. show that intratumoral CD103+ dendritic cells (DCs) highly express TIM-3. Anti-TIM-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells, thereby improving paclitaxel's therapeutic activity in breast cancer models.

KW - breast cancer

KW - chemotherapy

KW - dendritic cells

KW - galectin-9

KW - immunotherapy

KW - paclitaxel

KW - TIM-3

UR - http://www.scopus.com/inward/record.url?scp=85042419062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042419062&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2017.11.019

DO - 10.1016/j.ccell.2017.11.019

M3 - Article

VL - 33

SP - 60-74.e6

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -